Study of Pembrolizumab Following TACE in Primary Liver Carcinoma — PETAL

Primary Liver Carcinoma Clinical Trial

Official title:
A Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization in Primary Liver Carcinoma

Status Active, not recruiting

Clinical Trial Summary

Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed. The primary objective is to determine the safety and tolerability of pembrolizumab following TACE. The secondary objective is to evaluate the efficacy of pembrolizumab following TACE by improving progression-free survival rates as measured by modified response evaluation criteria in solid tumours (mRECIST) criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03397654
Study type	Interventional
Source	Imperial College London
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	January 28, 2018
Completion date	December 31, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02014025` - Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC	N/A
	Recruiting	`NCT06342414` - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer